Inflammatory Cytokines and Comorbidity Development in Breast Cancer Survivors Versus Noncancer Controls: Evidence for Accelerated Aging?
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Purpose: The sequelae of cancer treatment may increase systemic inflammation and create a phenotype at increased risk of functional decline and comorbidities, leading to premature mortality. Little is known about how this trajectory compares with natural aging among peers of the same age without cancer. This longitudinal study investigated proinflammatory cytokines and comorbidity development over time among breast cancer survivors and a noncancer control group. Methods: Women (N = 315; 209 with breast cancer and 106 in the control group) were recruited at the time of their work-up for breast cancer; they completed the baseline questionnaire, interview, and blood draw (lipopolysaccharide-stimulated production of interleukin [IL] -6, tumor necrosis factor-α, and IL-1β). Measures were repeated 6 and 18 months after primary cancer treatment (cancer survivors) or within a comparable time frame (control group). Results: There were no baseline differences in comorbidities or cytokines between survivors and the control group. Over time, breast cancer survivors had significantly higher tumor necrosis factor-α and IL-6 compared with the control group. Survivors treated with surgery, radiation, and chemotherapy accumulated a significantly greater burden of comorbid conditions and suffered greater pain associated with inflammation over time after cancer treatment than did the control group. Conclusion: Survivors who had multimodal treatment had higher cytokines and comorbidities, suggestive of accelerated aging. Comorbidities were related to inflammation in this sample, which could increase the likelihood of premature mortality. Given that many comorbidities take years to develop, future research with extended follow-up beyond 18 months is necessary to examine the evidence of accelerated aging in cancer survivors and to determine the responsible mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013) · Cell · doi:10.1016/j.cell.2013.05.039 · Cited by 14,982
Validation of a combined comorbidity index
Charlson, M., Szatrowski, T. P., Peterson, J., & Gold, J. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90129-5 · Cited by 6,587
Small sample inference for fixed effects from restricted maximum likelihood
Kenward, M. G., & Roger, J. H. (1997) · Biometrics · doi:10.2307/2533558 · Cited by 4,552
Aging, Cellular Senescence, and Cancer
Campisi, J. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183653 · Cited by 2,954
Runowicz, C. D., Leach, C. R., Henry, N. L., Henry, K. S., Mackey, H. T., Cowens-Alvarado, R. L., Cannady, R. S., Pratt-Chapman, M. L., Edge, S. B., Jacobs, L. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.3809 · Cited by 1,071
Ferrucci, L., Penninx, B. W. J. H., Volpato, S., Harris, T. B., Bandeen‐Roche, K., Balfour, J., Leveille, S. G., Fried, L. P., & Md, J. M. G. (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50605.x · Cited by 618
Inflammatory markers and the risk of Alzheimer disease: The Framingham Study
Tan, Z. S., Beiser, A. S., Vasan, R. S., Roubenoff, R., Dinarello, C. A., Harris, T. B., Benjamin, E. J., Au, R., Kiel, D. P., Wolf, P. A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000263217.36439.da · Cited by 440
Inflammatory Markers and Incident Mobility Limitation in the Elderly
Penninx, B. W. J. H., Kritchevsky, S. B., Newman, A. B., Nicklas, B. J., Simonsick, E. M., Rubin, S., Nevitt, M., Visser, M., Harris, T., & Pahor, M. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52308.x · Cited by 326
Payette, H., Roubenoff, R., Jacques, P. F., Dinarello, C. A., Wilson, P. W. F., Abad, L. W., & Harris, T. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2003.51407.x · Cited by 245
Kiecolt-Glaser, J. K., Belury, M. A., Andridge, R., Malarkey, W. B., Hwang, B. S., & Glaser, R. (2012) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.05.011 · Cited by 233
Self-citation
Cited by
Measuring Aging and Identifying Aging Phenotypes in Cancer Survivors
Guida, J. L., Ahles, T. A., Belsky, D., Campisi, J., Cohen, H. J., DeGregori, J., Fuldner, R., Ferrucci, L., Gallicchio, L., Gavrilov, L., et al. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz136 · Cited by 216
Alfano, C. M., Leach, C. R., Smith, T. G., Miller, K. D., Alcaraz, K. I., Cannady, R. S., Wender, R. C., & Brawley, O. W. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21548 · Cited by 179
Self-citationFrailty and aging in cancer survivors
Ness, K. K., & Wogksch, M. D. (2020) · Translational Research · doi:10.1016/j.trsl.2020.03.013 · Cited by 124
“Cytokine levels were associated with comorbidities in this population who were on average 55 years of age.[78] Survivors of childhood ALL (N=10) treated with radiation,[79] and HCT survivors (N=63) also demonstrate increased expression of p16INK4a, associated with radiation exposure, with higher doses of chemotherapy…”
BackgroundAriffin, H., Azanan, M. S., Abd Ghafar, S. S., Oh, L., Lau, K. H., Thirunavakarasu, T., Sedan, A., Ibrahim, K., Chan, A., Chin, T. F., et al. (2017) · Cancer · doi:10.1002/cncr.30857 · Cited by 99
“In an 18-month longitudinal follow-up study of 209 breast cancer survivors (mean age, 55 years), Alfano et al reported significantly elevated TNF-a and IL6 with associated accumulation of comorbidities, suggestive of an aging phenotype.(34) We speculate that the collateral cellular damage induced by cancer and its tre…”
BackgroundZhu, J., Wang, F., Shi, L., Cai, H., Zheng, Y., Zheng, W., Bao, P., & Shu, X.-O. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05541-5 · Cited by 31
Metadata
- Authors
- Alfano, C. M., Peng, J., Andridge, R. R., Lindgren, M. E., Povoski, S. P., Lipari, A. M., Agnese, D. M., Farrar, W. B., Yee, L. D., Carson, W. E., & Kiecolt-Glaser, J. K.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-01-10
- Volume
- 35
- Issue
- 2
- Pages
- 149-156
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2558437605
- Cited by
- 95
- References
- 10
- FWCI
- 3.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inflammatory Cytokines and Comorbidity Development in Breast Cancer Survivors Versus Noncancer Controls: Evidence for Accelerated Aging? https://app.cochat.ai/papers/10.1200/jco.2016.67.1883
- The paper
- Alfano, C. M., Peng, J., Andridge, R. R., Lindgren, M. E., Povoski, S. P., Lipari, A. M., Agnese, D. M., Farrar, W. B., Yee, L. D., Carson, W. E., & Kiecolt-Glaser, J. K. (2017). Inflammatory Cytokines and Comorbidity Development in Breast Cancer Survivors Versus Noncancer Controls: Evidence for Accelerated Aging? Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.67.1883
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.